Genmab — Februar 2016
-
10 IND kandidater for de næste 4 år
-
acceleration fase in 2018-19 will also include immunoincology
-
half of development
programs are immunoncology -
Jan on FIRE
-
tiso likely gonna be shared with SGEN
-
den var ny!!!
-
Helt ny!
-
-
haha
-
Godt CC
-
vi kan vist konkludere, at journalisterne bare kopierede fra hinanden omkring tiso
-
der var rigtig mange guldkorn - han åbnede endnu mere for IND-kasssen
-
GEN ligger lige i røven af APM i mæglerstatistikken i C20. Det er sandelig blevet nye tider...
-
kunne vi ikke udlede, at dara's launch - og Jans kommentarer om salgsudviklingen i januar - tilsammen giver et billede af, at dara er 110% på sporet til at indfri de høje forventninger?
-
yderligere fik vi de voldsomme bull-signaler på castor/pollux, og egentlig også nogle interessante bi-bemærkninger omkring europæisk godkendelse
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind